Gadi Saarony - PAREXEL International Senior Vice President - Clinical Research Services

Mr. Gadi Saarony is Senior Vice President Clinical Research of Parexel International Corporationrationration. In this position, Mr. Saarony is responsible for global project leadership and for clinical operations for our CRS business unit. From January 2008 to July 2012, Mr. Saarony was Corporationrationrate Vice President and World Wide Head, PAREXEL Consulting and Medical Communications . From July 2007 to January 2008, he served as Corporationrationrate Vice President and General Manager, PAREXEL Consulting. Prior to this, Mr. Saarony held various positions of increasing responsibility with the Company. Prior to joining the Company in 2003, Mr. Saarony was Director of Consulting Services for Habama, Inc. and Associate Director, Strategy, with Ernst Young, LLP, Inc. He graduated from Rider University with a degree in Economics and holds a masters degree in International Business from The American Graduate School of International Business .
Age: 47  President Since 2012      
781 487-9900

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Umang VohraDr Reddys Laboratories Ltd
Andrew FentonZoetis
K RaoDr Reddys Laboratories Ltd
Alejandro BernalZoetis
Douglas McCorkleRegeneron Pharmaceuticals
Raghav ChariDr Reddys Laboratories Ltd
James MichaudPerrigo Company Plc
Joyce LeeZoetis
Sripada ChandrasekharDr Reddys Laboratories Ltd
Grainne QuinnPerrigo Company Plc
Sandra BeatyZoetis
Thomas FarringtonPerrigo Company Plc
John GrayVertex Pharmaceuticals Incorpor
Ronald JanishPerrigo Company Plc
Charles MilsteinVertex Pharmaceuticals Incorpor
Paul SilvaVertex Pharmaceuticals Incorpor
Stefan WeiskopfZoetis
Glenn DavidZoetis
John WesolowskiPerrigo Company Plc
Ganadhish KamatDr Reddys Laboratories Ltd
Michael PariniVertex Pharmaceuticals Incorpor

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.